

Prenatal Multivitamin Supplementation and Rates of Congenital Anomalies: A Meta-Analysis

Y. Ingrid Goh, HBSc,^{1,2} Enkelejd Bollano, MD,² Thomas R. Einarson, PhD,^{1,2} Gideon Koren, MD¹⁻⁵

¹Department of Pharmaceutical Sciences, University of Toronto, Toronto ON

²The Motherisk Program, Division of Clinical Pharmacology/Toxicology, The Hospital for Sick Children, Toronto ON

³Faculty of Medicine, University of Toronto, Toronto ON

⁴Ivey Chair in Molecular Toxicology, University of Western Ontario, London ON

⁵Department of Medicine, University of Western Ontario, London ON

Abstract

Background: The use of folic acid-fortified multivitamin supplements has long been associated with decreasing the risk of neural tube defects. Several studies have also proposed the effectiveness of these supplements in preventing other birth defects; however, such effects have never been systematically examined.

Objective: We conducted a systematic review and meta-analysis to evaluate the protective effect of folic acid-fortified multivitamin supplements on other congenital anomalies.

Methods: We searched Medline, PubMed, EMBASE, Toxline, Healthstar, and Cochrane databases for studies describing the outcome of pregnancies in women using multivitamin supplements that were published in all languages from January 1966 to July 2005. The references from all collected articles were reviewed for additional articles. Two independent reviewers who were blinded to the source and identity of the articles extracted data based on predetermined inclusion and exclusion criteria. Using a random effects model, rates of congenital anomalies in babies born to women who were taking multivitamin supplements were compared with rates in the offspring of controls who were not.

Results: From the initial search, 92 studies were identified; 41 of these met the inclusion criteria. Use of multivitamin supplements provided consistent protection against neural tube defects (random effects odds ratio [OR] 0.67, 95% confidence intervals [95% CI] 0.58–0.77 in case control studies; OR 0.52, 95% CI 0.39–0.69 in cohort and randomized controlled studies), cardiovascular defects (OR 0.78, 95% CI 0.67–0.92 in case control studies; OR 0.61, 95% CI 0.40–0.92 in cohort and randomized controlled studies), and limb defects (OR 0.48, 95% CI 0.30–0.76 in case control studies; OR 0.57, 95% CI 0.38–0.85 in cohort and randomized controlled studies). For cleft palate, case control studies showed OR 0.76 (95% CI 0.62–0.93), and cohort and randomized controlled studies showed OR 0.42 (95% CI 0.06–2.84); for oral cleft with or without cleft palate, case control studies showed OR 0.63 (95% CI 0.54–0.73), and cohort and randomized controlled studies showed OR 0.58 (95% CI 0.28–1.19); for urinary tract anomalies, case control studies showed OR 0.48 (95% CI

0.30–0.76), and cohort and randomized controlled studies showed OR 0.68 (95% CI 0.35–1.31); and for congenital hydrocephalus case control studies showed OR 0.37 (95% CI 0.24–0.56), and cohort and randomized controlled studies showed OR 1.54 (95% CI 0.53–4.50). No effects were shown in preventing Down syndrome, pyloric stenosis, undescended testis, or hypospadias.

Conclusion: Maternal consumption of folic acid-containing prenatal multivitamins is associated with decreased risk for several congenital anomalies, not only neural tube defects. These data have major public health implications, because until now fortification of only folic acid has been encouraged. This approach should be reconsidered.

Résumé

Contexte : L'utilisation de suppléments multivitaminiques fortifiés à l'acide folique est depuis longtemps associée à la baisse du risque d'anomalies du tube neural. Plusieurs études ont également proposé l'efficacité de ces suppléments pour la prévention d'autres anomalies congénitales; cependant, ces effets n'ont jamais fait l'objet d'un examen systématique.

Objectif : Nous avons mené un examen et une méta-analyse systématiques afin d'évaluer l'effet protecteur des suppléments multivitaminiques fortifiés à l'acide folique sur d'autres anomalies congénitales.

Méthodes : Nous avons mené des recherches dans les bases de données Medline, PubMed, EMBASE, Toxline, Healthstar et Cochrane afin d'y recenser les études (qui ont été publiées, toutes langues confondues, entre janvier 1966 et juillet 2005) décrivant les issues de grossesse chez les femmes qui ont utilisé des suppléments multivitaminiques. Les références de tous les articles recensés ont fait l'objet d'une analyse afin d'y trouver des articles additionnels. Deux analystes indépendants, n'ayant pas été mis au courant de la source ni de l'identité des articles en question, ont procédé à l'extraction de données en fonction de critères d'inclusion et d'exclusion prédéterminés. Les taux d'anomalies congénitales chez les enfants nés de femmes ayant pris des suppléments multivitaminiques ont été comparés, au moyen d'un modèle à effets aléatoires, à ceux de témoins n'en ayant pas pris.

Résultats : La recherche initiale a permis l'identification de 92 études; 41 d'entre elles ont satisfait aux critères d'inclusion. L'utilisation de suppléments multivitaminiques a offert une protection uniforme contre les anomalies du tube neural (rapport de cotes des effets aléatoires [RC], 0,67, intervalles de confiance [IC] à 95 %, 0,58–0,77, dans les études cas-témoins; RC, 0,52, IC à 95 %, 0,39–0,69, dans les études de cohorte et les essais

Key Words: Prenatal multivitamins, congenital anomalies, meta-analysis

Competing Interests: None declared.

Received on May 26, 2006

Accepted on June 5, 2006

comparatifs randomisés), les anomalies cardiovasculaires (RC, 0,78, IC à 95 %, 0,67–0,92, dans les études cas-témoins; RC, 0,61, IC à 95 %, 0,40–0,92, dans les études de cohorte et les essais comparatifs randomisés) et les anomalies affectant les membres (RC, 0,48, IC à 95 %, 0,30–0,76, dans les études cas-témoins; RC, 0,57, IC à 95 %, 0,38–0,85, dans les études de cohorte et les essais comparatifs randomisés). Dans le cas de la fente palatine, les études cas-témoins ont indiqué un RC de 0,76 (IC à 95 %, 0,62–0,93) et les études de cohorte et les essais comparatifs randomisés ont indiqué un RC de 0,42 (IC à 95 %, 0,06–2,84); dans le cas de la fente orale avec ou sans fente palatine, les études cas-témoins ont indiqué un RC de 0,63 (IC à 95 %, 0,54–0,73) et les études de cohorte et les essais comparatifs randomisés ont indiqué un RC de 0,58 (IC à 95 %, 0,28–1,19); dans le cas des anomalies du tractus urinaire, les études cas-témoins ont indiqué un RC à 0,48 (IC à 95 %, 0,30–0,76) et les études de cohorte et les essais comparatifs randomisés ont indiqué un RC de 0,68 (IC à 95 %, 0,35–1,31); et dans le cas de l'hydrocéphalie congénitale, les études cas-témoins ont indiqué un RC de 0,37 (IC à 95 %, 0,24–0,56) et les études de cohorte et les essais comparatifs randomisés ont indiqué un RC de 1,54 (IC à 95 %, 0,53–4,50). Aucun effet préventif n'a été constaté en ce qui concerne le syndrome de Down, la sténose du pylore, la cryptorchidie ou l'hypospadias.

Conclusion : La consommation de multivitamines prénatales contenant de l'acide folique par la mère est associée à une baisse non seulement du risque d'anomalies du tube neural, mais également de celui d'anomalies congénitales graves. Ces données entraînent d'importantes conséquences en matière de santé publique puisque, jusqu'à présent, seule la fortification à l'acide folique a été favorisée. Cette approche devrait être remise en question.

J Obstet Gynaecol Can 2006;28(8):680–689

INTRODUCTION

One in 33 children born in Canada and the United States has a birth defect.^{1,2} In 2005, it was estimated that about 150 000 babies are born in North America each year with a birth defect.³ The burden of illness and the economic cost of birth defects are extremely high.^{4,5} More than a decade ago, the preventative role of maternal folate supplementation on the occurrence and the recurrence of neural tube defects was documented in several studies.^{6,7,8} Subsequently, preconceptional fortification with folic acid has been shown to reduce the rates of neural tube defects in North America.⁹

During the last decade, several studies have suggested that folic acid-fortified multivitamins may also prevent other congenital anomalies.¹⁰ Botto et al. suggested, on the basis of several studies, that there was a decreased risk for orofacial clefts, limb deficiencies, and cardiovascular abnormalities in babies whose mothers received multivitamin supplementation.¹¹ To date, however, no systematic review has been conducted to examine existing evidence for the potential of folic acid-containing multivitamins to decrease the risk of congenital anomalies other than neural tube defects. The objective of the present study was to conduct a meta-analysis of studies comparing rates of congenital

malformation among women taking vitamin supplements with the rates in controls.

METHODS

We conducted a search of existing studies that focused on pre- and periconceptional maternal ingestion of multivitamins and the rates of malformation in the offspring. The outcome of interest was congenital malformations. All original research articles using randomized controlled trial, case control, or cohort studies were included. All selected articles contained reports of maternal intake of multivitamins during pregnancy, a control group, and raw data describing rates of healthy and malformed children. Articles that did not report usage of multivitamins during pregnancy, articles that focused on specific vitamins, articles describing mothers exposed to other known teratogens, review articles, letters to the editor, and data reports from abstracts or meetings were excluded.


Articles were searched using the terms “multivitamin,” “pregnancy,” and “malformation” in Medline (January 1966–July 2005), PubMed (1950–July 2005), EMBASE (January 1980–July 2005), Toxline (January 1960–July 2005), Healthstar (January 1966–July 2005), and Cochrane database in all languages. The references from all collected articles were reviewed to locate other original studies.

Two reviewers blinded to authors' names, institution, and journal title assessed all of the articles collected using the selection criteria described above. Data were extracted from these articles to collection forms in 2 × 2 tables. In cases of discrepancy between the reviewers that were not resolved by discussion, the article in question was reviewed by a third blinded reviewer. The odds ratios and 95% confidence intervals were calculated for each study using Review Manager 4.2.7 (2004, The Cochrane Collaboration). Homogeneity among effects was tested by calculating chi-square.

RESULTS


Ninety-two articles were compiled from initial searches of the databases and reference review. Forty-one studies were eligible for the meta-analysis based on the inclusion and exclusion criteria.^{12–53} There were 27 case control studies, four randomized control trials, and 10 cohort studies. Fifty-one articles were excluded because they did not report malformation rates, focused specifically on folic acid, did not contain a control group, were review articles, or contained data that were identical to previous studies by the same authors. The use of multivitamin supplementation by the mothers from before the time of conception was associated with a consistent protective effect against neural tube defects (odds ratio [OR] 0.67, 95% confidence interval [CI] 0.58–0.77 in case control studies; OR 0.52, 95% CI 0.39–0.69

Figure 1. Maternal multivitamin consumption before and in first trimester of pregnancy and risk of NTD in their children (case control studies)




NTD: neural tube defects; OR: odds ratio; CI: confidence interval.

Figure 2. Maternal multivitamin consumption before and in first trimester of pregnancy and risk of NTD in their children (cohort and RCT studies)




NTD: neural tube defects; RCT: randomized controlled trials; OR: odds ratio; CI: confidence interval.

Figure 3. Maternal multivitamin consumption before and in first trimester of pregnancy and risk of cleft palate in their children (case control studies)




OR: odds ratio; CI: confidence interval

Figure 4. Maternal multivitamin consumption before and in first trimester of pregnancy and risk of cleft palate in their children (cohort and RCT studies)




RCT: randomized controlled trials; OR: odds ratio; CI: confidence interval.

Figure 5. Maternal multivitamin consumption before and in first trimester of pregnancy and risk of cleft lip with or without palate in their children (case control studies)




OR: odds ratio; CI: confidence interval.

Figure 6. Maternal multivitamin consumption before and in first trimester of pregnancy and risk of cleft lip with or without palate in their children (cohort and RCT studies)




RCT: randomized controlled trials; OR: odds ratio; CI: confidence interval.

Figure 7. Maternal multivitamin consumption before and in first trimester of pregnancy and risk of urinary tract anomalies in their children (case control studies)




OR: odds ratio; CI: confidence interval.

Figure 8. Maternal multivitamin consumption before and in first trimester of pregnancy and risk of urinary tract anomalies in their children (cohort and RCT studies)




RCT: randomized controlled trials; OR: odds ratio; CI: confidence interval.

Figure 9. Maternal multivitamin consumption before and in first trimester of pregnancy and risk of cardiovascular defects in their children (case control studies)




OR: odds ratio; CI: confidence interval.

Figure 10. Maternal multivitamin consumption before and in first trimester of pregnancy and risk of cardiovascular defects in their children (cohort and RCT studies)




RCT: randomized controlled trials; OR: odds ratio; CI: confidence interval.

Figure 11. Maternal multivitamin consumption before and in first trimester of pregnancy and risk of limb defects in their children (case control studies)




OR: odds ratio; CI: confidence interval.

Figure 12. Maternal multivitamin consumption before and in first trimester of pregnancy and risk of limb defects in their children (cohort and RCT studies)




RCT: randomized controlled trials; OR: odds ratio; CI: confidence interval.

Figure 13. Maternal multivitamin consumption before and in first trimester of pregnancy and risk of congenital hydrocephalus in their children (case control studies)




OR: odds ratio; CI: confidence interval.

Figure 14. Maternal multivitamin consumption before and in first trimester of pregnancy and risk of congenital hydrocephalus in their children (cohort and RCT studies)



RCT: randomized controlled trials; OR: odds ratio; CI: confidence interval.

Figure 15. Maternal multivitamin consumption in first trimester of pregnancy and risk of NTD in their children (case control studies)



NTD: neural tube defects; OR: odds ratio; CI: confidence interval.

in cohort and randomized controlled studies), cardiovascular defects (OR 0.78, 95% CI 0.67–0.92 in case control studies; OR 0.61, 95% CI 0.40–0.92 in cohort and randomized controlled studies), and limb defects (OR 0.48, 95% CI 0.30–0.76 in case control studies; OR 0.57, 95% CI 0.38–0.85 in cohort and randomized controlled studies). Multivitamin supplementation beginning before pregnancy showed a less consistent protective effect against cleft palate (OR 0.76, 95% CI 0.62–0.93 in case control studies; OR 0.42, 95% CI 0.06–2.84 in cohort and randomized controlled studies), oral cleft with or without cleft palate (OR 0.63, 95% CI 0.54–0.73 in case control studies; OR 0.58, 95% CI 0.28–1.19 in cohort and randomized controlled studies), urinary tract anomalies (OR 0.48, 95% CI 0.30–0.76 in case control studies; OR 0.68, 95% CI 0.35–1.31 in cohort and randomized controlled studies), and congenital hydrocephalus (OR 0.37, 95% CI 0.24–0.56 in case control studies; OR 1.54, 95% CI 0.53–4.50 in cohort and randomized controlled studies) (Figures 1–14). In addition, women who began supplementation in the first trimester after learning of the pregnancy showed a protective effect for neural tube defects (OR 0.80, 95% CI 0.72–0.89) (Figure 15). There was no heterogeneity among the studies.

In contrast, multivitamin supplementation was not associated with a protective effect for Down syndrome (OR 0.56, 95% CI 0.26–1.19 in cohort and randomized controlled studies), congenital pyloric stenosis (OR 1.10, 95% CI 0.79–1.53 in case control studies; OR 0.20, 95% CI 0.02–1.68 in cohort and randomized controlled studies), undescended testis (OR 0.81, 95% CI 0.40–1.64 in cohort studies), and hypospadias (OR 0.44, 95% CI 0.13–1.43 in cohort and randomized controlled studies).

DISCUSSION

The present meta-analysis confirms initial impressions that the use of multivitamins fortified with folic acid by women before conception and continuing through the first trimester is associated with a decrease in several serious major malformations. To our knowledge, this is the first systematic review and meta-analysis to examine and document these protective effects.

The majority of the studies included in the meta-analysis were case control studies, although there were also several randomized controlled trials and cohort studies. Not surprisingly, case control studies are more sensitive in showing significant effects for preventing specific malformations than cohort or randomized studies. The observation that all the studies for the majority of endpoints were statistically homogenous lends credibility to the documented effects. There was heterogeneity in the case control studies and

cohort studies examining neural tube defects (8 and 11 studies, respectively). Exclusion of one small case control study (Bower and Stanley¹⁷) and one small cohort study (Sheppard et al.⁴⁵), each of which showed no protective effect, renders the results homogeneous without changing the overall effect size. Moreover, we could not detect a publication bias by employing the funnel plot. Our study, however, is limited by the fact that multivitamin supplements in differing studies may have varied in their composition.

Presently, there are widely publicized recommendations by various authorities for women to supplement with folate at daily doses of at least 0.4mg (4 mg for women at higher risk) to reduce the risk of delivering a child with neural tube defects. In many centres women are advised to begin taking prenatal vitamin supplements when they decide to attempt to conceive, merely to allow them sufficient folate supplementation. It is currently impossible to discern whether folic acid or other vitamins are critical in the prevention of other birth defects.

Only a fraction of women currently take prenatal vitamin supplements at the time of conception, partly because one half of all pregnancies are unplanned. Serious consideration should be given to fortification of flour or other food staples with other vitamins in addition to folate. With increased surveillance of changes in malformation rates as a result of folate fortification, and subsequently larger cohorts, it will be possible to determine whether folate fortification itself is capable of protecting against birth defects other than neural tube defects.

CONCLUSION

The results of the present meta-analysis support the use of prenatal multivitamin preparations containing folic acid to reduce the incidence of several congenital anomalies, including neural tube defects, cardiovascular anomalies, oral cleft, urinary tract anomalies, congenital hydrocephalus, and limb defects. Randomized trials will be necessary to prove which specific vitamin(s) render protective effects.

ACKNOWLEDGEMENTS

Supported by grants from the Canadian Institutes of Health Research and the Research Leadership for Better Pharmacotherapy During Pregnancy and Lactation.

REFERENCES

1. Canadian Perinatal Surveillance System, Congenital Anomalies in Canada: A Perinatal Health Report, 2002. Available at: http://www.phac-aspc.gc.ca/publicat/cac-acc02/pdf/cac2002_e.pdf. Accessed September 1, 2005.
2. Department of Health and Human Services, Centers for Disease and Control Prevention. Available at: <http://www.cdc.gov/node.do/id/0900f3ec8000dffe>. Accessed September 1, 2005.

3. March of Dimes, Birth Defects. Available at: http://www.marchofdimes.com/pnhec/4439_1206.asp. Accessed September 1, 2005.
4. Kinsman SL, Doehring MC. The cost of preventable conditions in adults with spina bifida. *Eur J Pediatr Surg* 1996; Suppl 1:17–20.
5. Hunt O, Burden D, Hepper P, Johnston C. The psychosocial effects of cleft lip and palate: a systematic review. *Eur J Orthod* 2005; 27(3):274–85.
6. Laurence KM, Carter CO, David PA. Major central nervous system malformations in South Wales. II. Pregnancy factors, seasonal variation, and social class effects. *Br J Prev Soc Med* 1968;22(4):212–22.
7. Smithells RW, Sheppard S, Schorah CJ, Seller MJ, Nevin NC, Harris R, et al. Possible prevention of neural-tube defects by periconceptional vitamin supplementation. *Lancet* 1980;1(8164):339–40.
8. Laurence KM, James N, Miller MH, Tennant GB, Campbell H. Double-blind randomised controlled trial of folate treatment before conception to prevent recurrence of neural-tube defects. *Br Med J (Clin Res Ed)* 1981;282(6275):1509–11.
9. Mills JL, Signore C. Neural tube defect rates before and after food fortification with folic acid. *Birth Defects Res A Clin Mol Teratol* 2004; 70(11):844–5.
10. Czeizel AE. Periconceptional folic acid containing multivitamin supplementation. *Eur J Obstet Gynecol Reprod Biol* 1998;78(2):151–61.
11. Botto LD, Olney RS, Erickson JD. Vitamin supplements and the risk for congenital anomalies other than neural tube defects. *Am J Med Genet C Semin Med Genet* 2004;125(1):12–21.
12. Botto LD, Khoury MJ, Mulinare J, Erickson JD. Periconceptional multivitamin use and the occurrence of conotruncal heart defects: results from a population-based, case control study. *Pediatrics* 1996; 98(5):911–7.
13. Botto LD, Mulinare J, Erickson JD. Occurrence of congenital heart defects in relation to maternal multivitamin use. *Am J Epidemiol* 2000;151(9):878–84.
14. Botto LD, Lynberg MC, Erickson JD. Congenital heart defects, maternal febrile illness, and multivitamin use: a population-based study. *Epidemiology* 2001;12(5):485–90.
15. Botto LD, Mulinare J, Erickson JD. Occurrence of omphalocele in relation to maternal multivitamin use: a population-based study. *Pediatrics* 2002;109(5):904–8.
16. Botto LD, Mulinare J, Yang Q, Liu Y, Erickson JD. Autosomal trisomy and maternal use of multivitamin supplements. *Am J Med Genet A* 2004; 125(2):113–6.
17. Bower C, Stanley FJ. Periconceptional vitamin supplementation and neural tube defects; evidence from a case control study in Western Australia and a review of recent publications. *J Epidemiol Community Health* 1992;46(2):157–61.
18. Briggs RM. Vitamin supplementation as a possible factor in the incidence of cleft lip/palate deformities in humans. *Clin Plast Surg* 1976;4(4):647–52.
19. Correa A, Botto L, Liu Y, Mulinare J, Erickson JD. Do multivitamin supplements attenuate the risk for diabetes-associated birth defects? *Pediatrics* 2003; (5 Part 2):1146–51.
20. Czeizel AE. Prevention of the first occurrence of neural-tube defects by periconceptional vitamin supplementation. *N Engl J Med* 1992;327(26):1832–5.
21. Czeizel AE. Prevention of congenital abnormalities by periconceptional multivitamin supplementation. *BMJ* 1993; 306(6893):1645–8.
22. Czeizel AE, Dudas I, Metneki J. Pregnancy outcomes in a randomised controlled trial of periconceptional multivitamin supplementation. Final report. *Arch Gynecol Obstet* 1994;255(3):131–9.
23. Czeizel AE. Reduction of urinary tract and cardiovascular defects by periconceptional multivitamin supplementation. *Am J Med Genet* 1996;62(2):179–83.
24. Czeizel AE, Timar L, Sarkozi A. Dose-dependent effect of folic acid on the prevention of orofacial clefts. *Pediatrics* 1999;104(6):e66.
25. Czeizel AE. Folic acid and human malformations: misunderstandings. *Reprod Toxicol* 2001;15(4):441–4.
26. Czeizel AE, Dobo M, Vargha P. Hungarian cohort-controlled trial of periconceptional multivitamin supplementation shows a reduction in certain congenital abnormalities. *Birth Defects Res A Clin Mol Teratol* 2004;(11):853–61.
27. Hayes C, Werler MM, Willett WC, Mitchell AA. Case control study of periconceptional folic acid supplementation and oral clefts. *Am J Epidemiol* 1996;143(12):1229–34.
28. Itikala PR, Watkins ML, Mulinare J, Moore CA, Liu Y. Maternal multivitamin use and orofacial clefts in offspring. *Teratology* 2001;63(2):79–86.
29. Central Technical Co-ordinating Unit, ICMRCentral Technical Co-ordinating Unit, ICMR. Multicentric study of efficacy of periconceptional folic acid containing vitamin supplementation in prevention of open neural tube defects from India. *Indian J Med Res* 2000;112:206–11.
30. Khoury MJ, Shaw GM, Moore CA, Lammer EJ, Mulinare J. Does periconceptional multivitamin use reduce the risk of neural tube defects associated with other birth defects? data from two population-based case control studies. *Am J Med Genet* 1996;61(1):30–6.
31. Kirke PN, Daly LE, Elwood JH. A randomised trial of low dose folic acid to prevent neural tube defects. The Irish Vitamin Study Group. *Arch Dis Child* 1992;67(12):1442–6.
32. Li DK, Daling JR, Mueller BA, Hickok DE, Fantel AG, Weiss NS. Periconceptional multivitamin use in relation to the risk of congenital urinary tract anomalies. *Epidemiology* 1995;6(3):212–8.
33. Loffredo LC, Souza JM, Freitas JA, Mossey PA. Oral clefts and vitamin supplementation. *Cleft Palate Craniofac J* 2001;38(1):76–83.
34. Mills JL, Rhoads GG, Simpson JL, Cunningham GC, Conley MR, Lassman MR, et al. The absence of a relation between the periconceptional use of vitamins and neural-tube defects. National Institute of Child Health and Human Development Neural Tube Defects Study Group. *N Engl J Med* 1989;321(7):430–5.
35. Milunsky A, Jick H, Jick SS, Bruell CL, MacLaughlin DS, Rothman KJ, et al. Multivitamin/folic acid supplementation in early pregnancy reduces the prevalence of neural tube defects. *JAMA* 1989;262(20):2847–52.
36. [No authors listed] Prevention of neural tube defects: results of the Medical Research Council Vitamin Study. MRC Vitamin Study Research Group. *Lancet* 1991; 338(8760):131–7.
37. Mulinare J, Cordero JF, Erickson JD, Berry RJ. Periconceptional use of multivitamins and the occurrence of neural tube defects. *JAMA* 1988;260(21):3141–5.
38. Scanlon KS, Ferencz C, Loffredo CA, Wilson PD, Correa-Villasenor A, Khoury MJ, et al. Preconceptional folate intake and malformations of the cardiac outflow tract. Baltimore-Washington Infant Study Group. *Epidemiology* 1998;9(1):95–8.
39. Seller MJ, Nevin NC. Periconceptional vitamin supplementation and the prevention of neural tube defects in south-east England and Northern Ireland. *J Med Genet* 1984;21(5):325–30.
40. Shaw GM, O'Malley CD, Wasserman CR, Tolarova MM, Lammer EJ. Maternal periconceptional use of multivitamins and reduced risk for conotruncal heart defects and limb deficiencies among offspring. *Am J Med Genet* 1995;59(4):536–45.
41. Shaw GM, Schaffer D, Velie EM, Morland K, Harris JA. Periconceptional vitamin use, dietary folate, and the occurrence of neural tube defects. *Epidemiology* 1995;6(3):219–26.

42. Shaw GM, Lammer EJ, Wasserman CR, O'Malley CD, Tolarova MM. Risks of orofacial clefts in children born to women using multivitamins containing folic acid periconceptionally. *Lancet* 1995;346(8972):393-6.
43. Shaw GM, Velie EM, Wasserman CR. Risk for neural tube defect-affected pregnancies among women of Mexican descent and white women in California. *Am J Public Health* 1997;87(9):1467-71.
44. Shaw GM, Zhu H, Lammer EJ, Yang W, Finnell RH. Genetic variation of infant reduced folate carrier (A80G) and risk of orofacial and conotruncal heart defects. *Am J Epidemiol* 2003; 158(8):747-52.
45. Sheppard S, Nevin NC, Seller MJ, Wild J, Smithells RW, Read AP, et al. Neural tube defect recurrence after 'partial' vitamin supplementation. *J Med Genet* 1989;26(5):326-9.
46. Smithells RW, Sheppard S, Schorah CJ, Seller MJ, Nevin NC, Harris R, et al. Possible prevention of neural-tube defects by periconceptional vitamin supplementation. *Lancet* 1980;1(8164):339-40.
47. Smithells RW, Sheppard S, Schorah CJ, Seller MJ, Nevin NC, Harris R, et al. Apparent prevention of neural tube defects by periconceptional vitamin supplementation. *Arch Dis Child* 1981;56(12):911-8.
48. Thompson SJ, Torres ME, Stevenson RE, Dean JH, Best RG. Periconceptional multivitamin folic acid use, dietary folate, total folate and risk of neural tube defects in South Carolina. *Ann Epidemiol* 2003;13(6):412-8.
49. Tolarova M, Harris J. Reduced recurrence of orofacial clefts after periconceptional supplementation with high-dose folic acid and multivitamins. *Teratology* 1995;51(2):71-8.
50. van Rooij IA, Vermeij-Keers C, Kluijtmans LA, Ocke MC, Zielhuis GA, Goorhuis-Brouwer SM, et al. Does the interaction between maternal folate intake and the methylenetetrahydrofolate reductase polymorphisms affect the risk of cleft lip with or without cleft palate? *Am J Epidemiol* 2003;157(7):583-91.
51. Werler MM, Shapiro S, Mitchell AA. Periconceptional folic acid exposure and risk of occurrent neural tube defects. *JAMA* 1993;269(10):1257-61.
52. Werler MM, Hayes C, Louik C, Shapiro S, Mitchell AA. Multivitamin supplementation and risk of birth defects. *Am J Epidemiol* 1999;150(7):675-82.
53. Wild J, Read AP, Sheppard S, Seller MJ, Smithells RW, Nevin NC, et al. Recurrent neural tube defects, risk factors and vitamins. *Arch Dis Child* 1986;61(5):440-4.